Could a simple injection stop type 1 diabetes before it starts?
NCT ID NCT05683990
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a drug called Diamyd, given as injections into lymph nodes, to see if it is safe and can prevent type 1 diabetes in children aged 8 to 17 who are at high risk. Only 5 participants are enrolled, and the study focuses on safety and whether the drug can stop the disease from progressing. It is an early step, not a proven prevention.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Diamyd (a drug injected into lymph nodes to train the immune system)
- What this could lead to
- If it works, this could point toward a way to delay or prevent type 1 diabetes in children who are genetically at risk.
- What could go wrong
- This is a very small early trial with only 5 participants, so results may not apply broadly. The drug could cause side effects or fail to stop diabetes progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lund University/CRC, Skåne University Hospital,
Malmö, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a stress hormone be behind the hidden danger of low blood sugar?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?
- Could music be medicine for the injured brain?
- Can engineered immune cells tame autoimmune disease?
- Can a peptide tame type 1 diabetes?
- Blood test may spot hidden nerve damage behind chronic constipation